Nevada will collect $3.3 million as part of a multi-state settlement against the manufacturer of an anti-psychotic medication.
Nevada is among 36 states sharing the record $181 million settlement with Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson.
Attorney General Catherine Cortez Masto said Thursday that Nevadans have a right to know the risks presented by atypical anti-psychotic drugs.
An investigation found that Janssen improperly marketed four anti-psychotic drugs for unapproved or off-label uses, including treatment of Alzheimer’s disease, dementia, depression and anxiety.
Janssen did not admit wrongdoing but the company has agreed to change how it promotes and markets the drugs.